Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: Hepatology. 2021 Aug 27;74(6):3284–3300. doi: 10.1002/hep.32071

TABLE 2.

Liver Biochemistries of Patients

Patient No. Disease Control Diagnosis Age (years) Sex  Total Bilirubin (mg/dL)  ALT (IU/L)  AST (IU/L)
1 Hepatoblastoma 3.32 Female 0.40 29 27
2 Hepatoblastoma 3.39 Male 0.20 46 63
3 Methylmalonic acidemia 1.65 Female 0.60 22 61
4 Ornithine transcarbamylase deficiency 2.56 Female 0.30 312 331
PNAC Group Diagnosis Age (years) Sex  Total Bilirubin (mg/dL)  ALT (IU/L)  AST (IU/L)
5 PNAC 0.10 Female 12.10 101.00 118.00
6 PNAC 0.25 Female 8.30 226.00 213.00
7 PNAC 0.08 Male 4.00 48.00 82.00
8 PNAC 1.02 Male 63.2 172 430.00
9 PNAC 0.18 Female 4.80 182.00 230.00
10 PNAC 0.30 Female 5.70 36.00 70.00
11 PNAC 0.50 Male 2.90 485.00 396.00
Group Total Bilirubin (mg/dL) (mean ± SEM) ALT (IU/L) (mean ± SEM) AST (IU/L) (mean ± SEM)

Disease controls 0.38 ±0.09 102.25 ± 70.10 120.50 ± 70.65
PNAC 14.43 ± 8.21 178.57 ± 57.65 219.86 ± 55.03
Liver Biochemistry Disease Controls vs. PNAC P Value

Total bilirubin <0.0001
ALT ns
AST ns

Abbreviation: ns, not significant.